Lybra Bio
Reshaping the autoimmune
skin diseases treatment landscape
We are pioneering a new era in autoimmune skin disease therapy, combining advanced immunology with cutting-edge biomaterials.
About Lybra
Our therapeutic platform, developed at Harvard and MIT, enables targeted, non-invasive delivery of therapeutics that restore immune balance at the source.
​
By leveraging the power of regulatory T cells (Tregs), we are addressing the root causes of immune dysregulation—offering patients long-lasting, precise, and patient-friendly solutions to conditions like alopecia areata, vitiligo, and psoriasis.
01
The Problem
Autoimmune skin diseases like alopecia areata, vitiligo, and psoriasis affect millions worldwide, leading to emotional distress, social stigma, and limited treatment options. Traditional therapies, including broad immunosuppressants, painful injections, and inconsistent topical treatments, fail to provide long-lasting immune balance and often come with significant side effects.
02
The Solution
By harnessing the body's natural ability to regulate immune responses, our microneedles-enabled platform delivers cargos directly to affected areas, ensuring a targeted, localized effect while minimizing systemic exposure. This precise modulation of immune pathways allows us to achieve sustained therapeutic effects, offering patients long-lasting relief that continues even after treatment ends.
​
Designed for ease of use and patient comfort, our technology eliminates the need for injections or frequent systemic treatments, transforming how autoimmune skin diseases are managed.
Supporters
We are proud to collaborate with leading patient organizations, research institutions, and biotech groups to advance the frontiers of autoimmune skin disease therapy.
